Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:NOVN

Novan (NOVN) Stock Price, News & Analysis

Novan logo

About Novan Stock (NASDAQ:NOVN)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
7.19 million shs
Average Volume
602,421 shs
Market Capitalization
$2.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Novan, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Durham, North Carolina.

Receive NOVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novan and its competitors with MarketBeat's FREE daily newsletter.

NOVN Stock News Headlines

Novartis AG
Novartis AG Registered Shares
The real reason Elon is fully endorsing Trump
Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump.
Novartis AG Registered Shares NOVN
Novan reaches deals to sell assets in bankruptcy case
Firm Retention Summary: Novan
See More Headlines

NOVN Stock Analysis - Frequently Asked Questions

Novan, Inc. (NASDAQ:NOVN) announced its quarterly earnings data on Monday, May, 15th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.22. The firm had revenue of $3.17 million for the quarter, compared to the consensus estimate of $6.19 million. Novan had a negative net margin of 128.61% and a negative trailing twelve-month return on equity of 700.28%.

Novan (NOVN) raised $46 million in an initial public offering (IPO) on Wednesday, September 21st 2016. The company issued 3,800,000 shares at $11.00-$13.00 per share. Piper Jaffray acted as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Novan investors own include Meta Platforms (META), Bionano Genomics (BNGO), Inovio Pharmaceuticals (INO), Tonix Pharmaceuticals (TNXP), NIO (NIO), Tesla (TSLA) and Zomedica (ZOM).

Company Calendar

Last Earnings
5/15/2023
Today
10/31/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NOVN
Employees
90
Year Founded
N/A

Profitability

Net Income
$-31,310,000.00
Net Margins
-128.61%
Pretax Margin
-128.39%

Debt

Sales & Book Value

Annual Sales
$24.71 million
Book Value
$0.19 per share

Miscellaneous

Free Float
27,651,000
Market Cap
$2.64 million
Optionable
Not Optionable
Beta
-0.06

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:NOVN) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners